2024-05-02T08:13:09-05:00 2023-06-30 042571780 AAFCPAS INC 50 WASHINGTON STREET WESTBOROUGH MA 01581 990 2022-07-01 813250208 INSTITUTE FOR PROTEIN INNOVATION INC INST 6173147970 4 BLACKFAN CIRCLE 921 BOSTON MA 02111 KENNETH FASMAN PHD PRESIDENT & CEO 6173147970 2024-04-03 1 KENNETH FASMAN PHD XXX-XX-XXXX 0 THOMAS F MULDOON CPA P01561688 5083669100 2024-04-03 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z KENNETH FASMAN PHD 4 BLACKFAN CIRCLE 921 BOSTON MA 02111 77009397 0 X HTTPS://PROTEININNOVATION.ORG X 2016 MA TO ADVANCE PROTEIN SCIENCE TO ACCELERATE RESEARCH AND IMPROVE HUMAN HEALTH. 10 9 44 30 0 0 206730 235625 763276 41577 4208427 3745590 0 0 5178433 4022792 0 0 0 0 4878128 5979685 0 0 0 6107903 7217965 10986031 13197650 -5807598 -9174858 191011980 196826153 1081048 5622463 189930932 191203690 THE INSTITUTE FOR PROTEIN INNOVATION IS ADVANCING PROTEIN SCIENCE TO ACCELERATE RESEARCH AND IMPROVE HUMAN HEALTH. 0 0 8256292 41577 THE INSTITUTE PROVIDES ACADEMIA AND INDUSTRY WITH SYNTHETIC ANTIBODIES AND DEEP PROTEIN EXPERTISE IN CONJUNCTION WITH BOSTON CHILDREN'S HOSPITAL AND OTHER ACADEMIC AND INDUSTRY PARTNERS. SINCE INCEPTION, THE INSTITUTE HAS PRODUCED AND CHARACTERIZED THOUSANDS OF SYNTHETIC RECOMBINANT ANTIBODIES AGAINST HUNDREDS OF PROTEIN TARGETS VIA ITS HIGH-THROUGHPUT ANTIBODY DISCOVERY PLATFORM. THE INSTITUTE IS COLLABORATING WITH RESEARCHERS IN INDUSTRY AND ACADEMIA TO USE THESE ANTIBODIES TO ACCELERATE RESEARCH AND ENABLE RESEARCH ON NEW THERAPEUTICS THAT IMPROVE HUMAN HEALTH. 8256292 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 25 0 1 44 1 0 0 0 0 0 0 0 0 0 0 0 0 X 10 9 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X EGESTA FABER 6176518351 4 BLACKFAN CIRCLE 921 BOSTON MA 02111 ROB MEIJERS DIRECTOR OF ANTIBODY PLATFORM 40.00 X 378560 0 40696 TRISHA GURA DIR. COMMUNICATIONS 40.00 X 271623 0 18760 JOSEPH BERTELSEN DIRECTOR OF ANTIBODY INITIATIVES 40.00 X 248857 0 41274 STEPHEN FUCHS INTERIM ED (UNTIL 10/20/22) 40.00 X 233513 0 32915 KENNETH FASMAN PRESIDENT & CEO/DIRECTOR 40.00 X X 205330 0 4382 HAISIN ZHU SCIENTIST 40.00 X 164374 0 36183 YAMINA BERCHICHE SENIOR SCIENTIST 40.00 X 155290 0 27996 SAMANTHA SINGER CHAIR 1.00 X X 0 0 0 MICHAEL O'HARA TREASURER 1.00 X X 0 0 0 DR TIMOTHY A SPRINGER CO-FOUNDER/DIRECTOR 1.00 X 0 0 0 DR STEVEN C ALMO DIRECTOR 1.00 X 0 0 0 DR JEFFREY FLIER DIRECTOR 1.00 X 0 0 0 DR MAYKIN HO DIRECTOR 1.00 X 0 0 0 DR AMIR NASHAT DIRECTOR 1.00 X 0 0 0 DR STEPHEN BLACKLOW DIRECTOR 1.00 X 0 0 0 ISRAEL ROZEN DIRECTOR 1.00 X 0 0 0 1657547 0 202206 17 0 1 0 HUTCHISON PLLC 3110 EDWARDS MILL ROAD SUITE 300 RALEIGH NC 27612 LEGAL SERVICES 273694 MINTZ LEVIN COHEN FERRIS GLOVSKY AND POP ONE FINANCIAL CENTER BOSTON MA 02111 LEGAL SERVICES 183508 CRJ INC 283 RIDGE STREET ARLINGTON MA 02474 INTERIM DIRECTOR OF FINANCE 113313 3 208375 27250 235625 LICENSING REVENUE 541700 41577 41577 41577 5057558 5057558 71586455 88182 72767323 219282 -1180868 -131100 -1311968 -1311968 4022792 41577 0 3745590 938867 938867 3884480 3063708 820772 184528 137594 46934 649432 457039 192393 322378 206328 116050 732275 732275 46106 46106 321879 321879 1019201 120248 898953 1739242 1234862 504380 869472 851657 17815 LAB MATERIALS & SERVICE 2105251 1961867 143384 OTHER 384539 222989 161550 13197650 8256292 4941358 0 2480196 839409 4518200 1567574 65407 57448 25967 10075 564573 420519 7322661 3391068 4179433 3931593 179033564 184539122 1297480 144640 4162933 191011980 196826153 630096 1186001 450952 4436462 1081048 5622463 X 189930932 191203690 189930932 191203690 191011980 196826153 -9174858 10447616 0 X X 0 1 X 1 0 X BOSTON CHILDREN'S HOSPITAL BOSTON MA PART 1, LINE 4: THE INSTITUTE IS A MEDICAL RESEARCH ORGANIZATION FOR ITS TAXABLE YEAR ENDED JUNE 30, 2023, AS ITS EXPENDITURES OF $13,124,778 ON A CASH BASIS FOR THAT YEAR EXCEEDED THE MRO REQUIREMENT OF $6,504,281 (3.5% OF ITS ENDOWMENT). RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 307191 160049 147142 7015470 3231019 3784451 3931593 OPERATING LEASE LIABILITY 4436462 4436462 X 14148529 10447616 10447616 3700913 321879 321879 4022792 12875771 0 12875771 321879 321879 13197650 PART X, LINE 2: THE INSTITUTE ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH ASC TOPIC, INCOME TAXES. THIS STANDARD CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS AND PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE FINANCIAL STATEMENTS REGARDING A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THE INSTITUTE HAS DETERMINED THAT THERE ARE NO UNCERTAIN TAX POSITIONS WHICH QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS AT JUNE 30, 2023. THE INSTITUTE'S INFORMATION RETURNS ARE SUBJECT TO EXAMINATION BY THE FEDERAL AND STATE JURISDICTIONS. X X X 0 0 0 0 0 0 0 0 0 ROB MEIJERS DIRECTOR OF ANTIBODY PLATFORM 248560 0 130000 0 0 0 14404 0 26292 0 419256 0 0 0 TRISHA GURA DIR. COMMUNICATIONS 221623 0 50000 0 0 0 8716 0 10044 0 290383 0 0 0 JOSEPH BERTELSEN DIRECTOR OF ANTIBODY INITIATIVES 248857 0 0 0 0 0 15342 0 25932 0 290131 0 0 0 STEPHEN FUCHS INTERIM ED (UNTIL 10/20/22) 183513 0 50000 0 0 0 11005 0 21910 0 266428 0 0 0 KENNETH FASMAN PRESIDENT & CEO/DIRECTOR 80330 0 125000 0 0 0 0 0 4382 0 209712 0 0 0 HAISIN ZHU SCIENTIST 164374 0 0 0 0 0 9891 0 26292 0 200557 0 0 0 YAMINA BERCHICHE SENIOR SCIENTIST 155290 0 0 0 0 0 0 0 27996 0 183286 0 0 0 FORM 990, PART I, LINE 6: THE INSTITUTE DOES NOT FORMALLY TRACK VOLUNTEERS BUT HAS INCLUDED THE NUMBER OF BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD MEMBERS THAT ARE UNCOMPENSATED. FORM 990, PART VI, SECTION A, LINE 2 TIMOTHY SPRINGER AND AMIR NASHAT HAVE A BUSINESS RELATIONSHIP AS DEFINED BY THE IRS. AMIR NASHAT AND JEFFREY FLIER ALSO HAVE A BUSINESS RELATIONSHIP AS DEFINED BY THE IRS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE INSTITUTE'S AUDIT FIRM BASED ON INFORMATION PROVIDED BY MANAGEMENT. THE DIRECTOR OF FINANCE, CONTROLLER AND CEO REVIEWS THE FORM 990 IN DRAFT FOR ACCURACY AND PROVIDES AND RECOMMENDED CHANGES TO THE EXTERNAL AUDIT FIRM FOR INCORPORATION. ONCE CORRECTIONS AND REVISIONS ARE MADE, THE FORM IS THEN PROVIDED TO THE INSTITUTE'S LEGAL COUNSEL AND AUDIT AND FINANCE COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT AND FINANCE COMMITTEE CUSTOMARILY MEETS WITH THE EXTERNAL AUDIT FIRM TO REVIEW THE DRAFT. AFTER APPROVAL BY THE AUDIT AND FINANCE COMMITTEE, THE FORM 990 IN FINAL FORM IS SUBMITTED TO EACH MEMBER OF THE BOARD OF DIRECTORS FOR REVIEW AND APPROVAL PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE INSTITUTE HAS A CONFLICT OF INTEREST POLICY THAT APPLIES TO ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES. THE POLICY IS MONITORED BY THE INSTITUTE'S CONFLICT OF INTEREST COMMITTEE AND LEGAL COUNSEL. THE POLICY REQUIRES EACH DIRECTOR TO SUBMIT, ON AN ANNUAL BASIS, A COI DISCLOSURE OF ANY SITUATIONS THAT COULD GIVE RISE TO THE APPEARANCE OF A CONFLICT OF INTEREST FOR REVIEW BY LEGAL COUNSEL AND THE COI COMMITTEE. EACH DIRECTOR HAS A CONTINUING OBLIGATION, UNDER THE POLICY, TO DISCLOSE ANY POTENTIAL CONFLICTS OF INTEREST AT THE TIME THEY ARISE DURING THE COURSE OF THE YEAR TO THE COI COMMITTEE. ALL SUCH SUBMISSIONS ARE REVIEWED BY LEGAL COUNSEL AND THE COI COMMITTEE FOR A DETERMINATION AND APPROPRIATE ACTION. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION OF THE EXECUTIVE DIRECTOR IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, ALL OF WHOM ARE INDEPENDENT OF EMPLOYMENT OF THE INSTITUTE. THE BOARD UTILIZES THE RADFORD COMPENSATION SURVEY DATA TO DETERMINE THE APPROPRIATE COMPENSATION RANGE FOR THE POSITION. FORM 990, PART VI, SECTION C, LINE 19 THE INSTITUTE'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XII, LINE 2C: THE BOARD OF DIRECTORS IS RESPONSIBLE FOR OVERSIGHT OF THE AUDIT PROCESS AND REVIEW OF THE FINANCIAL STATEMENTS.